Strong Buy Rated Stocks
MAZE is part of our Strong Buy Rated Stocks screen, indicating it has a strong buy ratings from analysts and supporting business quality.
MAZE THERAPEUTICS INC (MAZE) Stock Price & Overview
NASDAQ:MAZE • US5787841007
Current stock price
28.71 USD
-0.34 (-1.17%)
At close:
28.71 USD
0 (0%)
After Hours:
The current stock price of MAZE is 28.71 USD. Today MAZE is down by -1.17%. In the past month the price decreased by -36.62%. In the past year, price increased by 216.54%.
MAZE Key Statistics
52-Week Range6.71 - 53.65
Current MAZE stock price positioned within its 52-week range.
1-Month Range28 - 53.65
Current MAZE stock price positioned within its 1-month range.
- Market Cap
- 1.382B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.23
- Dividend Yield
- N/A
MAZE Stock Performance
Today
-1.17%
1 Week
-9.46%
1 Month
-36.62%
3 Months
-27.81%
Longer-term
6 Months +5.90%
1 Year +216.54%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
MAZE Stock Chart
MAZE Stock Screens
MAZE currently appears in the following ChartMill screener lists.
RSI Oversold Stocks
MAZE is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
MAZE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to MAZE. When comparing the yearly performance of all stocks, MAZE is one of the better performing stocks in the market, outperforming 95.19% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
MAZE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MAZE. MAZE has an excellent financial health rating, but there are some minor concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MAZE Earnings
Next Earnings DateN/A
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.65
Revenue Reported
EPS Surprise 10.70%
Revenue Surprise %
MAZE Forecast & Estimates
12 analysts have analysed MAZE and the average price target is 61.71 USD. This implies a price increase of 114.94% is expected in the next year compared to the current price of 28.71.
Analysts
Analysts86.67
Price Target61.71 (114.94%)
EPS Next Y0.88%
Revenue Next YearN/A
MAZE Groups
Sector & Classification
MAZE Financial Highlights
Over the last trailing twelve months MAZE reported a non-GAAP Earnings per Share(EPS) of -3.23.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)3.40M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.03% | ||
| ROA | 0.81% | ||
| ROE | 0.9% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%96.45%
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A
MAZE Ownership
Ownership
Inst Owners88.17%
Shares48.12M
Float42.04M
Ins Owners1.88%
Short Float %8.54%
Short Ratio4.72
MAZE Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MAZE
Company Profile
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. The company is headquartered in South San Francisco, California and currently employs 125 full-time employees. The company went IPO on 2025-01-31. The firm is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Company Info
IPO: 2025-01-31
MAZE THERAPEUTICS INC
171 Oyster Point Boulevard, Suite 300
South San Francisco CALIFORNIA US
Employees: 125
Phone: 16508505070
MAZE THERAPEUTICS INC / MAZE FAQ
What does MAZE THERAPEUTICS INC do?
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. The company is headquartered in South San Francisco, California and currently employs 125 full-time employees. The company went IPO on 2025-01-31. The firm is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
What is the stock price of MAZE THERAPEUTICS INC today?
The current stock price of MAZE is 28.71 USD. The price decreased by -1.17% in the last trading session.
Does MAZE stock pay dividends?
MAZE does not pay a dividend.
How is the ChartMill rating for MAZE THERAPEUTICS INC?
MAZE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for MAZE stock?
12 analysts have analysed MAZE and the average price target is 61.71 USD. This implies a price increase of 114.94% is expected in the next year compared to the current price of 28.71.
What is the GICS sector and industry of MAZE stock?
MAZE THERAPEUTICS INC (MAZE) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of MAZE stock?
MAZE THERAPEUTICS INC (MAZE) has a market capitalization of 1.38B USD. This makes MAZE a Small Cap stock.